ZLAB250117P7500
- 0.00
- 0.000.00%
Zai Lab Newsroom
Bank of America Securities Sticks to Their Buy Rating for Zai Lab (ZLAB)
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $29
Bank of America Securities Keeps Their Buy Rating on Zai Lab (ZLAB)
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $50
Zai Lab Analyst Ratings
Leerink Partners Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $72
Analysts' Top Healthcare Picks: Universal Health (UHS), Zai Lab (ZLAB)
Zai Lab Is Maintained at Overweight by JP Morgan
Zai Lab Analyst Ratings
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $38
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Cuts Target Price to $38
Strong Buy Rating for Zai Lab: Outperforming Vyvgart Sales and Promising Global Pipeline Fuel Optimism
Morgan Stanley Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $50
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $25
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $25
Buy Rating Affirmed for Zai Lab on Robust Drug Sales Growth and Strong Market Position
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Announces Target Price $25
Buy Rating Affirmed for Zai Lab on Strong Financials and Promising Pipeline Developments
Zai Lab Analyst Ratings
Bank of America Securities Sticks to Their Buy Rating for Zai Lab (ZLAB)